The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
Open accessAbstract
In Brief Purpose: On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims of this study are to evaluate the accuracy of imaging in determining the resectability of PDAC and to determine the surgical and clinicopathologic outcomes of pancreatic resections after neoadjuvant FOLFIRINOX therapy. Patients and Methods: Clinicopathologic data were retrospectively collected for surgical PDAC patients receiving neoadjuvant FOLFIRINOX or no neoadjuvant therapy between April 2011 and February 2014. Americas Hepato-Pancreato-Biliary Association/Society of Surgical Oncology/Society for Surgery of the Alimentary Tract consensus guidelines defined LA and borderline. Imaging was reviewed by a blinded senior pancreatic surgeon. Results: Of 188 patients undergoing resection for PDAC, 40 LA/borderline received FOLFIRINOX and 87 received no neoadjuvant therapy. FOLFIRINOX resulted in a significant decrease in tumor size, yet 19 patients were still classified as LA and 9 as borderline. Despite post-FOLFIRINOX imaging suggesting continued unresectability, 92% had an R0 resection. When compared with no neoadjuvant therapy, FOLFIRINOX resulted in significantly longer operative times (393 vs 300 minutes) and blood loss (600 vs 400 mL), but significantly lower operative morbidity (36% vs 63%) and no postoperative pancreatic fistulas. Length of stay (6 vs 7 days), readmissions (20% vs 30%), and mortality were equivalent (1% vs 0%). On final pathology, the FOLFIRINOX group had a significant decrease in lymph node positivity (35% vs 79%) and perineural invasion (72% vs 95%). Median follow-up was 11 months with a significant increase in overall survival with FOLFIRINOX. Conclusions: After neoadjuvant FOLFIRINOX imaging no longer predicts unresectability. Traditional pathologic predictors of survival are improved, and morbidity is decreased in comparison to patients with clearly resectable cancers at the time of presentation. The study evaluates the accuracy of imaging in determining the resectability of pancreatic adenocarcinoma and determines the surgical outcomes of pancreatic resections after neoadjuvant FOLFIRINOX therapy. Imaging does not predict unresectability, and traditional pathologic predictors of survival are improved in comparison to patients with clearly resectable cancers at the time of presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Dindo, D., Demartines, N., & Clavien, P.-A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133083.54934.ae · Cited by 31,378
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
1423 Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Institution Experience
Winter, J. M., Cameron, J. L., Campbell, K. A., Arnold, M. A., Chang, D. C., Coleman, J., Hodgin, M. B., Sauter, P. K., Hruban, R. H., Riall, T. S., et al. (2006) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2006.08.018 · Cited by 1,489
Self-citationCallery, M. P., Chang, K. J., Fishman, E. K., Talamonti, M. S., William Traverso, L., & Linehan, D. C. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0408-6 · Cited by 902
Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
Katz, M. H. G., Pisters, P. W. T., Evans, D. B., Sun, C. C., Lee, J. E., Fleming, J. B., Vauthey, N. J., Abdalla, E. K., Crane, C. H., Wolff, R. A., et al. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.12.020 · Cited by 827
Konstantinidis, I. T., Warshaw, A. L., Allen, J. N., Blaszkowsky, L. S., Castillo, C. F.-D., Deshpande, V., Hong, T. S., Kwak, E. L., Lauwers, G. Y., Ryan, D. P., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318263da2f · Cited by 424
Self-citation
Cited by
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
Suker, M., Beumer, B. R., Sadot, E., Marthey, L., Faris, J. E., Mellon, E. A., El-Rayes, B. F., Wang-Gillam, A., Lacy, J., Hosein, P. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00172-8 · Cited by 939
Self-citationMultidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Katz, M. H. G., Shi, Q., Ahmad, S. A., Herman, J. M., Marsh, R. D. W., Collisson, E., Schwartz, L., Frankel, W., Martin, R., Conway, W., et al. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2016.1137 · Cited by 448
Metadata
- Authors
- Ferrone, C. R., Marchegiani, G., Hong, T. S., Ryan, D. P., Deshpande, V., McDonnell, E. I., Sabbatino, F., Santos, D. D., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Faris, J. E., Goyal, L., Kwak, E. L., Murphy, J. E., Ting, D. T., Wo, J. Y., Zhu, A. X., Warshaw, A. L., Lillemoe, K. D., & Castillo, C. F.-D.
- Venue
- Annals of Surgery
- Published
- 2015-01
- Volume
- 261
- Issue
- 1
- Pages
- 12-17
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2012005360
- Cited by
- 842
- References
- 22
- FWCI
- 28.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer. https://app.cochat.ai/papers/10.1097/sla.0000000000000867
- The paper
- Ferrone, C. R., Marchegiani, G., Hong, T. S., Ryan, D. P., Deshpande, V., McDonnell, E. I., Sabbatino, F., Santos, D. D., Allen, J. N., Blaszkowsky, L. S., Clark, J. W., Faris, J. E., Goyal, L., Kwak, E. L., Murphy, J. E., Ting, D. T., Wo, J. Y., Zhu, A. X., Warshaw, A. L., . . . Castillo, C. F.-D. (2015). Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer. Annals of Surgery. https://doi.org/10.1097/sla.0000000000000867
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.